Canaccord lowered the firm’s price target on Cybin (CYBN) to $86 from $96 and keeps a Buy rating on the shares. The firm said they reported results and he key update was that the company has started its PARADIGM Phase 3 program for CYB003 (deuterated psilocybin analog) as an adjunct treatment for major depressive disorder (MDD).
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYBN: